APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Therapeutic Antibodies and Proteins

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Therapeutic Antibodies and Proteins Market Outlook and Growth Opportunities 2026

Report ID 174031840420 December 2025192 pages

Choose your research edition.

Industry ResearchRecombinant Therapeutic Antibodies and Proteins Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Therapeutic Antibodies and Proteins Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Recombinant Therapeutic Antibodies and Proteins Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Therapeutic Antibodies and Proteins Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Therapeutic Antibodies and Proteins Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Recombinant Therapeutic Antibodies and Proteins market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Therapeutic Antibodies and Proteins is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Therapeutic Antibodies and Proteins market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Therapeutic Antibodies and Proteins market include Biogen, Novo Nordisk, Amgen, Pfizer, Eli Lilly, Roche, Merck, Johnson and Johnson and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Recombinant Therapeutic Antibodies and Proteins market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Therapeutic Antibodies and Proteins and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Therapeutic Antibodies and Proteins revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Recombinant Therapeutic Antibodies and Proteins market.

Recombinant Therapeutic Antibodies and Proteins Segment by Company

Biogen

Novo Nordisk

Amgen

Pfizer

Eli Lilly

Roche

Merck

Johnson and Johnson

Sanofi

Abbott

Recombinant Therapeutic Antibodies and Proteins Segment by Type

Plasma Protein

Fusion Proteins

Coagulation Factors

Enzyme

Hormones

Monoclonal Antibodies

Others

Recombinant Therapeutic Antibodies and Proteins Segment by Application

Enzyme

Monoclonal Antibodies

Hormones

Coagulation Factors

Fusion Proteins

Plasma Protein

Others

Recombinant Therapeutic Antibodies and Proteins Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Recombinant Therapeutic Antibodies and Proteins status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Recombinant Therapeutic Antibodies and Proteins key companies, revenue, market share, and recent developments.

3. To split the Recombinant Therapeutic Antibodies and Proteins breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Recombinant Therapeutic Antibodies and Proteins market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Therapeutic Antibodies and Proteins significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Therapeutic Antibodies and Proteins competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Therapeutic Antibodies and Proteins market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Therapeutic Antibodies and Proteins and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Therapeutic Antibodies and Proteins.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Therapeutic Antibodies and Proteins industry.

Chapter 3: Detailed analysis of Recombinant Therapeutic Antibodies and Proteins company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Recombinant Therapeutic Antibodies and Proteins in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Recombinant Therapeutic Antibodies and Proteins in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Therapeutic Antibodies and Proteins Industry Trends Table 2. Recombinant Therapeutic Antibodies and Proteins Industry Drivers Table 3. Recombinant Therapeutic Antibodies and Proteins Industry Opportunities and Challenges Table 4. Recombinant Therapeutic Antibodies and Proteins Industry Restraints Table 5. Global Recombinant Therapeutic Antibodies and Proteins Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Therapeutic Antibodies and Proteins Revenue Share by Company (2021-2026) Table 7. Global Recombinant Therapeutic Antibodies and Proteins Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Recombinant Therapeutic Antibodies and Proteins Key Company Manufacturing Base & Headquarters Table 9. Global Recombinant Therapeutic Antibodies and Proteins Company, Product Type & Application Table 10. Global Recombinant Therapeutic Antibodies and Proteins Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Recombinant Therapeutic Antibodies and Proteins by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Plasma Protein Table 15. Significant Companies of Fusion Proteins Table 16. Significant Companies of Coagulation Factors Table 17. Significant Companies of Enzyme Table 18. Significant Companies of Hormones Table 19. Significant Companies of Monoclonal Antibodies Table 20. Significant Companies of Others Table 21. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 22. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type (2021-2026) & (US$ Million) Table 23. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type (2027-2032) & (US$ Million) Table 24. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type (2021-2026) Table 25. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type (2027-2032) Table 26. Significant Companies of Enzyme Table 27. Significant Companies of Monoclonal Antibodies Table 28. Significant Companies of Hormones Table 29. Significant Companies of Coagulation Factors Table 30. Significant Companies of Fusion Proteins Table 31. Significant Companies of Plasma Protein Table 32. Significant Companies of Others Table 33. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application (2021-2026) & (US$ Million) Table 35. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application (2027-2032) & (US$ Million) Table 36. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application (2021-2026) Table 37. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application (2027-2032) Table 38. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region (2021-2026) & (US$ Million) Table 40. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Region (2021-2026) Table 41. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region (2027-2032) & (US$ Million) Table 42. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Region (2027-2032) Table 43. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 44. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country (2021-2026) & (US$ Million) Table 45. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Market Share by Country (2021-2026) Table 46. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country (2027-2032) & (US$ Million) Table 47. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Market Share by Country (2027-2032) Table 48. Biogen Company Information Table 49. Biogen Business Overview Table 50. Biogen Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 52. Biogen Recent Development Table 53. Novo Nordisk Company Information Table 54. Novo Nordisk Business Overview Table 55. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 57. Novo Nordisk Recent Development Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 62. Amgen Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 67. Pfizer Recent Development Table 68. Eli Lilly Company Information Table 69. Eli Lilly Business Overview Table 70. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 72. Eli Lilly Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 77. Roche Recent Development Table 78. Merck Company Information Table 79. Merck Business Overview Table 80. Merck Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 82. Merck Recent Development Table 83. Johnson and Johnson Company Information Table 84. Johnson and Johnson Business Overview Table 85. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 87. Johnson and Johnson Recent Development Table 88. Sanofi Company Information Table 89. Sanofi Business Overview Table 90. Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 92. Sanofi Recent Development Table 93. Abbott Company Information Table 94. Abbott Business Overview Table 95. Abbott Recombinant Therapeutic Antibodies and Proteins Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio Table 97. Abbott Recent Development Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Recombinant Therapeutic Antibodies and Proteins Product Image Figure 2. Global Recombinant Therapeutic Antibodies and Proteins Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Therapeutic Antibodies and Proteins Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Plasma Protein Image Figure 8. Fusion Proteins Image Figure 9. Coagulation Factors Image Figure 10. Enzyme Image Figure 11. Hormones Image Figure 12. Monoclonal Antibodies Image Figure 13. Others Image Figure 14. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type (2021-2032) Figure 17. Enzyme Image Figure 18. Monoclonal Antibodies Image Figure 19. Hormones Image Figure 20. Coagulation Factors Image Figure 21. Fusion Proteins Image Figure 22. Plasma Protein Image Figure 23. Others Image Figure 24. Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application (2021-2032) Figure 27. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032) & (US$ Million) Figure 30. North America Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032) & (US$ Million) Figure 36. South America Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Years Considered Figure 124. Research Process Figure 125. Key Executives Interviewed

Scope & coverage.

Types
  • Plasma Protein
  • Fusion Proteins
  • Coagulation Factors
  • Enzyme
  • Hormones
  • Monoclonal Antibodies
  • Others
Applications
  • Enzyme
  • Monoclonal Antibodies
  • Hormones
  • Coagulation Factors
  • Fusion Proteins
  • Plasma Protein
  • Others
Companies covered
  • Biogen
  • Novo Nordisk
  • Amgen
  • Pfizer
  • Eli Lilly
  • Roche
  • Merck
  • Johnson and Johnson
  • Sanofi
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Therapeutic Antibodies and Proteins Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Therapeutic Antibodies and Proteins Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Recombinant Therapeutic Antibodies and Proteins Market Dynamics
  1. 2.1 Recombinant Therapeutic Antibodies and Proteins Industry Trends
  2. 2.2 Recombinant Therapeutic Antibodies and Proteins Industry Drivers
  3. 2.3 Recombinant Therapeutic Antibodies and Proteins Industry Opportunities and Challenges
  4. 2.4 Recombinant Therapeutic Antibodies and Proteins Industry Restraints
3 Recombinant Therapeutic Antibodies and Proteins Market by Company
  1. 3.1 Global Recombinant Therapeutic Antibodies and Proteins Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Therapeutic Antibodies and Proteins Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Therapeutic Antibodies and Proteins Company Ranking (2024-2026)
  4. 3.4 Global Recombinant Therapeutic Antibodies and Proteins Company Manufacturing Base and Headquarters
  5. 3.5 Global Recombinant Therapeutic Antibodies and Proteins Company Product Type and Application
  6. 3.6 Global Recombinant Therapeutic Antibodies and Proteins Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Recombinant Therapeutic Antibodies and Proteins Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Recombinant Therapeutic Antibodies and Proteins Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Recombinant Therapeutic Antibodies and Proteins Market by Type
  1. 4.1 Recombinant Therapeutic Antibodies and Proteins Type Introduction
  2. 4.1.1 Plasma Protein
  3. 4.1.2 Fusion Proteins
  4. 4.1.3 Coagulation Factors
  5. 4.1.4 Enzyme
  6. 4.1.5 Hormones
  7. 4.1.6 Monoclonal Antibodies
  8. 4.1.7 Others
  9. 4.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type
  10. 4.2.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Type (2021-2032)
  12. 4.2.3 Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type (2021-2032)
5 Recombinant Therapeutic Antibodies and Proteins Market by Application
  1. 5.1 Recombinant Therapeutic Antibodies and Proteins Application Introduction
  2. 5.1.1 Enzyme
  3. 5.1.2 Monoclonal Antibodies
  4. 5.1.3 Hormones
  5. 5.1.4 Coagulation Factors
  6. 5.1.5 Fusion Proteins
  7. 5.1.6 Plasma Protein
  8. 5.1.7 Others
  9. 5.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application
  10. 5.2.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.2.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Application (2021-2032)
  12. 5.2.3 Global Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application (2021-2032)
6 Recombinant Therapeutic Antibodies and Proteins Regional Value Analysis
  1. 6.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region (2021-2032)
  3. 6.2.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region: 2021-2026
  4. 6.2.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032)
  7. 6.3.2 North America Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032)
  10. 6.4.2 Europe Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032)
  16. 6.6.2 South America Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Country, 2025 VS 2032
7 Recombinant Therapeutic Antibodies and Proteins Country-level Value Analysis
  1. 7.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country (2021-2032)
  3. 7.2.1 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country (2021-2026)
  4. 7.2.2 Global Recombinant Therapeutic Antibodies and Proteins Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Recombinant Therapeutic Antibodies and Proteins Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen
  2. 8.1.1 Biogen Company Information
  3. 8.1.2 Biogen Business Overview
  4. 8.1.3 Biogen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Biogen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  6. 8.1.5 Biogen Recent Developments
  7. 8.2 Novo Nordisk
  8. 8.2.1 Novo Nordisk Company Information
  9. 8.2.2 Novo Nordisk Business Overview
  10. 8.2.3 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novo Nordisk Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  12. 8.2.5 Novo Nordisk Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Johnson and Johnson
  44. 8.8.1 Johnson and Johnson Company Information
  45. 8.8.2 Johnson and Johnson Business Overview
  46. 8.8.3 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Johnson and Johnson Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  48. 8.8.5 Johnson and Johnson Recent Developments
  49. 8.9 Sanofi
  50. 8.9.1 Sanofi Company Information
  51. 8.9.2 Sanofi Business Overview
  52. 8.9.3 Sanofi Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Sanofi Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  54. 8.9.5 Sanofi Recent Developments
  55. 8.10 Abbott
  56. 8.10.1 Abbott Company Information
  57. 8.10.2 Abbott Business Overview
  58. 8.10.3 Abbott Recombinant Therapeutic Antibodies and Proteins Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Abbott Recombinant Therapeutic Antibodies and Proteins Product Portfolio
  60. 8.10.5 Abbott Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst